A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.

ABSTRACT:

Purpose

Prospectively identifying who will benefit from adjuvant chemotherapy (ACT) would improve clinical decisions for non-small cell lung cancer (NSCLC) patients. In this study, we aim to develop and validate a functional gene set that predicts the clinical benefits of ACT in NSCLC.

Experimental design

An 18-hub-gene prognosis signature was developed through a systems biology approach, and its prognostic value was evaluated in six independent cohorts. The 18-hub-gene set was then integrated with genome-wide functional (RNAi) data and genetic aberration data to derive a 12-gene predictive signature for ACT benefits in NSCLC.

Results

Using a cohort of 442 stage I to III NSCLC patients who underwent surgical resection, we identified an 18-hub-gene set that robustly pr

SUBMITTER: Tang H 

PROVIDER: S-EPMC3619002 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature